Overview

Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of ISIS-PTP1BRx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.
Phase:
Phase 2
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.
Treatments:
Metformin